Penumbra, Inc. (PEN)
Market Cap | 10.31B |
Revenue (ttm) | 847.13M |
Net Income (ttm) | -2.00M |
Shares Out | 38.18M |
EPS (ttm) | -0.05 |
PE Ratio | n/a |
Forward PE | 277.78 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 278,274 |
Open | 267.21 |
Previous Close | 266.17 |
Day's Range | 264.77 - 270.70 |
52-Week Range | 114.87 - 274.71 |
Beta | 0.52 |
Analysts | Buy |
Price Target | 297.23 (+10.06%) |
Earnings Date | May 2, 2023 |
About PEN
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for PEN stock is "Buy." The 12-month stock price forecast is $297.23, which is an increase of 10.06% from the latest price.
News

Are These Medical Device Makers Getting Ready To Rally?
Large-cap medical device maker Stryker Corp. (NYSE: SYK) is consolidating along its 50-day moving average, a bullish sign as the stock takes a breather after a run-up that began last year.

Penumbra (PEN) Q4 Earnings Top Estimates, Sales Remain Robust
Penumbra's (PEN) sales during the fourth quarter reflect continued demand for its products. The 2023 outlook is encouraging as EPS improves despite macro challenges.

Penumbra (PEN) Q4 Earnings and Revenues Surpass Estimates
Penumbra (PEN) delivered earnings and revenue surprises of 14.29% and 1.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Penumbra, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results
ALAMEDA, Calif. , Feb. 23, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the fourth quarter and ful...

Should You Buy Penumbra (PEN) Ahead of Earnings?
Penumbra (PEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Penumbra, Inc. to Present at Citi's 2023 Healthcare Services, Medtech, Tools & HCIT Conference
ALAMEDA, Calif. , Feb. 16, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at Citi's 2023 Healthcare Services, Medtech, Tools & HCIT Co...

Penumbra (PEN) Earnings Expected to Grow: Should You Buy?
Penumbra (PEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 Low-Beta Stocks to Buy to Sail Through the Volatile Market
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Penumbra (PEN), Patria Investments (PAX), Lamb Weston (LW) and BJ's Wholesale (BJ) are poised to gain.

Penumbra, Inc. Schedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call for February 23, 2023
ALAMEDA, Calif. , Jan. 26, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2022 af...

PENUMBRA LAUNCHES LATEST INNOVATION IN MECHANICAL THROMBECTOMY: LIGHTNING FLASH™
Lightning Flash™ is the most advanced mechanical thrombectomy system on the market to address venous and pulmonary thrombus Next generation technology combines superior catheter design with the latest...

Penumbra, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference
ALAMEDA, Calif. , Dec. 19, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 41st Annual J.P.

Penumbra Launches First Hands-Free, Full Body Virtual Reality-Based Offering for Rehabilitation, Expanding REAL® System Platform
ALAMEDA, Calif.--(BUSINESS WIRE)--Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced the first full body, non-tethered immersive healthcare offe...

Penumbra (PEN) Tops Q3 Earnings and Revenue Estimates
Penumbra (PEN) delivered earnings and revenue surprises of 200% and 0.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Penumbra, Inc. Reports Third Quarter 2022 Financial Results
ALAMEDA, Calif. , Nov. 3, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the third quarter ended Sep...

Penumbra, Inc. to Present at the Jefferies London Healthcare Conference
ALAMEDA, Calif. , Nov. 1, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Jefferies London Healthcare Conference on Tuesday, Nov...

Analysts Estimate Penumbra (PEN) to Report a Decline in Earnings: What to Look Out for
Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Penumbra, Inc. Schedules Third Quarter 2022 Earnings Release and Conference Call for November 3, 2022
ALAMEDA, Calif. , Oct. 6, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the third quarter 2022 after market close...

Penumbra and Asahi Intecc Partner With Goal of Introducing Indigo™ System Including Lightning™ Intelligent Aspiration to Japan
ALAMEDA, Calif.--(BUSINESS WIRE)---- $PEN #penumbra--Penumbra and Asahi Intecc Co. will collaborate to introduce Penumbra's Indigo™ Aspiration System into the Japanese market upon regulatory approval.

Penumbra (PEN) Surges 6.2%: Is This an Indication of Further Gains?
Penumbra (PEN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Penumbra Announces European Launch of RED® Reperfusion Catheters for Stroke Care
ALAMEDA, Calif.--(BUSINESS WIRE)---- $PEN #penumbra--Penumbra's RED® Reperfusion Catheters are now commercially available in Europe.

Latest Data Demonstrates Penumbra System and RED® Reperfusion Catheters Effective for Broad Stroke Care
ALAMEDA, Calif.--(BUSINESS WIRE)---- $PEN #penumbra--Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, announced initial INSIGHT Registry data showing Penumbra's...

Penumbra, Inc. to Present at Upcoming Investor Conferences
ALAMEDA, Calif. , Aug. 24, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the following investor conferences on the dates and times...

Penumbra (PEN) Surpasses Q2 Earnings and Revenue Estimates
Penumbra (PEN) delivered earnings and revenue surprises of 114.29% and 1.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Penumbra, Inc. Reports Second Quarter 2022 Financial Results
ALAMEDA, Calif. , Aug. 4, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the second quarter ended Ju...

Penumbra, Inc. to Present at the Canaccord Genuity 42nd Annual Growth Conference
ALAMEDA, Calif. , July 27, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord Genuity 42nd Annual Growth Conference on We...